Fiasp and NovoLog are not the same medication, but they are closely related. Both contain the same active ingredient, insulin aspart, and both are made by Novo Nordisk. The key difference is that Fiasp includes an added ingredient, niacinamide (a form of vitamin B3), that speeds up how quickly the insulin gets absorbed into your bloodstream. This makes Fiasp act faster than NovoLog, earning it the classification of “ultra-rapid-acting” insulin rather than just “rapid-acting.”
Same Insulin, Different Speed
Insulin aspart is the molecule doing the work in both Fiasp and NovoLog. It’s a lab-made version of human insulin designed to act quickly after injection. Where the two products diverge is in their inactive ingredients. Fiasp’s formulation includes niacinamide, which helps the insulin absorb faster through the tissue under your skin. The result is a noticeably quicker onset of action.
Fiasp begins working in about 5 minutes and reaches its peak effect in roughly 30 minutes. NovoLog takes about 15 minutes to kick in and peaks between 1 and 3 hours. Both last about 3 to 5 hours total. That faster start matters most right around meals, when blood sugar rises quickly and you want your insulin to keep pace.
Meal Timing Is More Flexible With Fiasp
Because Fiasp absorbs faster, the FDA-approved dosing window is wider. You can inject Fiasp at the start of a meal or even up to 20 minutes after you begin eating. NovoLog, by contrast, is typically injected 5 to 10 minutes before a meal to give it a head start. For people who find pre-bolusing difficult or unpredictable (parents dosing young children, for instance, or anyone whose appetite is hard to predict), Fiasp’s flexibility can be a real advantage.
How They Compare for Blood Sugar Control
In clinical trials, Fiasp matched NovoLog for overall blood sugar control as measured by HbA1c. The FDA reviewed this data and confirmed that Fiasp was non-inferior to NovoLog, meaning it works at least as well over time. In one trial, mealtime Fiasp actually showed a small but statistically significant edge over mealtime NovoLog for HbA1c reduction.
Where Fiasp shows a clearer difference is in post-meal blood sugar spikes. Because it starts working sooner and reaches higher concentrations earlier, Fiasp tends to blunt that initial glucose surge better than NovoLog. For people who struggle with sharp blood sugar rises after eating, that faster action can smooth out the curve on a continuous glucose monitor.
Using Either Insulin in a Pump
Both Fiasp and NovoLog are approved for use in insulin pumps. Fiasp delivered through a pump produced blood sugar control that was non-inferior to NovoLog in a study of adults with type 1 diabetes. There are a few practical differences to keep in mind, though.
Fiasp in a pump reservoir needs to be changed at least every 6 days. It should not be exposed to temperatures above 98.6°F (37°C) in the reservoir, and it cannot be mixed with other insulins or diluents in the pump. One notable finding from clinical trials: adults using Fiasp in a pump reported more episodes of low blood sugar within the first hour after a meal compared to those using NovoLog. This makes sense given the faster onset, but it means pump settings like insulin-to-carb ratios or active insulin time may need adjustment when switching between the two.
Why Confusion Between Them Matters
Because Fiasp and NovoLog share the same active ingredient and the same manufacturer, medication mix-ups have occurred. Nursing publications have flagged this as a safety concern. Accidentally using one in place of the other can affect blood sugar timing. If you’re expecting NovoLog’s 15-minute onset and receive Fiasp instead (or vice versa), your meal timing and dosing strategy could be off.
The two insulins come in similar-looking packaging, which adds to the risk. If you use either one, it’s worth double-checking vial or pen labels, especially when picking up a new prescription or if your pharmacy switches suppliers.
Switching Between Fiasp and NovoLog
Because the active ingredient is identical, switching between the two is generally straightforward from a dosing standpoint. The total amount of insulin your body needs doesn’t change. What does change is the timing profile, so you may need to adjust when you dose relative to meals and how you set up pump parameters. Blood sugar monitoring should be tighter during the transition period to catch any patterns of highs or lows caused by the speed difference.
The pharmacokinetic differences between Fiasp and NovoLog seen in adults also hold true in children and adolescents with type 1 diabetes, based on FDA-reviewed data. So the same timing considerations apply across age groups.